LOADING
Tag: Ruxolitinib
Ruxolitinib Cream and the Eczema JAK Inhibitor Era
June 24, 2023
Janus kinase (JAK) inhibitors have been established a leading drug class in a number of chronic skin diseases. Recent data lends to one researcher’s perspective that one JAK inhibitor’s efficacy in eczema sets it in its own class—and another JAK inhibitor’s safety risks are not actually applicable to the rest available in dermatologic care. In […]
chat_bubble0 Comment
visibility310 Views
Why Ruxolitinib May Alter Atopic Dermatitis Care Options
October 21, 2022
Ruxolitinib cream 1.5% (Opezlura) was approved by the US Food and Drug Administration (FDA) this July for the treatment of nonsegmental vitiligo—a novel, breakthrough indication for a topical JAK inhibitor in a space with few options. Incyte’s agent may be next considered for a chronic skin disease with a more robust armamentarium: atopic dermatitis, which […]
chat_bubble0 Comment
visibility322 Views